MSC2015103B in Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Advanced Solid Tumor
Interventions
DRUG

MSC2015103B

Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.

DRUG

MSC2015103B

Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.

Trial Locations (3)

Unknown

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Karmanos Cancer Institute, Detroit

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT01453387 - MSC2015103B in Solid Tumors | Biotech Hunter | Biotech Hunter